medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2020, Number 4

<< Back Next >>

Rev Nefrol Dial Traspl 2020; 40 (4)

Bone-Mineral Metabolism in 4,620 Prevalent Patients in Chronic Hemodialysis in Argentina

del Valle EE, Spivacow FR, Peñalba A, Forrester M, Filannino G, Rosa DG, Mengarelli C

Language: Spanish
References: 18
Page: 295-303
PDF size: 455.84 Kb.


ABSTRACT

Introduction: Abnormalities of bone mineral metabolism begin from the early stages of CKD, causing the development of bone disease and increased morbidity and mortality of patients. Objectives: To know, in a representative sample of our hemodialysis patients, the prevalence of patients in the target range of PTH values, secondary hyperparathyroidism and adynamic bone disease according to the KDIGO guidelines, also evaluating the use of different drugs in the control of these alterations. Methods: 39 hemodialysis centers from our country participated, who sent the latest determinations of calcium, phosphorus and PTH and the medication received in the management of mineral metabolism. Results: 4620 prevalent hemodialysis patients › 18 years were included, mean age 57 years, men 57.4%. The means were calcemia 8.6 and phosphatemia 4.9 mg/dl. 56.7% and 50.3% were in the calcemia and phosphatemia range, respectively. The average PTH was 601 and the median 437 pg/ml. 50.5% had PTH in range, 15% below 150 pg/ml and 34.5% above 600 pg/ml. In relation to medication, 47% of the patients received calcium chelators with extreme use ranging from 4.5-8% in some centers to 83-94%. 28.8% received Sevelamer, calcitriol 38%, paricalcitol 11% and cinacalcet 20%, its use being variable according to the centers from 3% to 52%. Conclusion: the presence of secondary hyperpartyroidism was more frequent than desired, probably linked to the difficulty in the adequate use of medications.


REFERENCES

  1. Cannata-Andía J, Torregrosa JV. Spanish nephrologistsand the management of mineral and bone metabolismdisorders in chronic kidney disease. Nefrología. 2014;34(2):175-88. doi: 10.3265/Nefrologia.pre2014.Jan.12280.

  2. Kidney Disease: Improving Global Outcomes(KDIGO) CKD-MBD Work Group. KDIGO clinicalpractice guideline for the diagnosis, evaluation,prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney IntSuppl. 2009;76(113):S1-130. doi: 10.1038/ki.2009.188.

  3. Ott SM. Histomorphometric measurements of boneturnover, mineralization, and volume. Clin J AmSoc Nephrol. 2008;3(Suppl 3):S151-6. doi: 10.2215/CJN.04301206.

  4. Fouque D, Roth H, Pelletier S, London GM,Hannedouche T, Jean G, et al. Control of mineralmetabolism and bone disease in haemodialysis patients:which optimal targets? Nephrol Dial Transplant.2013;28(2):360-7. doi: 10.1093/ndt/gfs404.

  5. Fernández-Martín JL, Martínez-Camblor P, Dionisi1) Cannata-Andía J, Torregrosa JV. Spanish nephrologistsand the management of mineral and bone metabolismdisorders in chronic kidney disease. Nefrología.2014;34(2):175-88. doi: 10.3265/Nefrologia.pre2014.Jan.12280.2) Kidney Disease: Improving Global Outcomes(KDIGO) CKD-MBD Work Group. KDIGO clinicalpractice guideline for the diagnosis, evaluation,prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney IntSuppl. 2009;76(113):S1-130. doi: 10.1038/ki.2009.188.3) Ott SM. Histomorphometric measurements of boneturnover, mineralization, and volume. Clin J AmSoc Nephrol. 2008;3(Suppl 3):S151-6. doi: 10.2215/CJN.04301206.4) Fouque D, Roth H, Pelletier S, London GM,Hannedouche T, Jean G, et al. Control of mineralmetabolism and bone disease in haemodialysis patients:which optimal targets? Nephrol Dial Transplant.2013;28(2):360-7. doi: 10.1093/ndt/gfs404.5) Fernández-Martín JL, Martínez-Camblor P, DionisiMP, Floege J, Ketteler M, London G, et al.;COSMOS group. Improvement of mineral and bonemetabolism markers is associated with better survivalin haemodialysis patients: the COSMOS study.Nephrol Dial Transplant. 2015;30(9):1542-51. doi:10.1093/ndt/gfv099.

  6. Marinovich S, Bisigniano L, Hansen Krogh D, CeliaE, Tagliafichi V, Rosa Diez G, et al. Registro Argentinode Diálisis Crónica SAN-INCUCAI 2018. Informe2019. Buenos Aires: Sociedad Argentina de Nefrología,Instituto Nacional Central Único Coordinador deAblación e Implante, 2019. 268 p.

  7. Krishnasamy R, Hawley CM, Johnson DW. An updateon bone imaging and markers in chronic kidneydisease. Expert Rev Endocrinol Metab. 2016;11(6):455-66. doi: 10.1080/17446651.2016.1239527.

  8. 8.National Kidney Foundation. K/DOQI clinicalpractice guidelines for bone metabolism and diseasein children with chronic kidney disease. Am JKidney Dis. 2005;46(Suppl. 1):S1-153. doi: 10.1053/j.ajkd.2005.07.028

  9. National Kidney Foundation. K/DOQI clinicalpractice guidelines for bone metabolism and disease inchronic kidney disease. Am J Kidney Dis. 2003;42(4Suppl. 3):S1-201.

  10. Tentori F, Zepel L, Fuller DS, Wang M, Bieber BA,Robinson BM, et al. The DOPPS practice monitorfor US dialysis care: PTH levels and management ofmineral and bone disorder in US hemodialysis patients.Am J Kidney Dis. 2015;66(3):536-9. doi: 10.1053/j.ajkd.2015.07.011.

  11. Kalantar-Zadeh K, Kuwae N, Regidor DL, KovesdyCP, Kilpatrick RD, Shinaberger CS, et al. Survivalpredictability of time-varying indicators of bonedisease in maintenance hemodialysis patients. KidneyInt. 2006;70(4):771-80. doi: 10.1038/sj.ki.5001514.

  12. Floege J, Kim K, Ireland E, Chazot C, Drueke T,de Francisco A, et al. Serum iPTH, calcium andphosphate, and the risk of mortality in a Europeanhaemodialysis population. Nephrol Dial Transplant.2011;26(6):1948-55. doi: 10.1093/ndt/gfq219.

  13. Naves-Díaz M, Passlick-Deetjen J, Guinsburg A,Marelli C, Fernández-Martín JL, Rodríguez-PuyolD, et al. Calcium, phosphorus, PTH and death ratesin a large sample of dialysis patients from LatinAmerica. The CORES Study. Nephrol Dial Transplant.2011;26(6):1938-47. doi: 10.1093/ndt/gfq304.

  14. Tentori F, Blayney MJ, Albert JM, Gillespie BW, KerrPG, Bommer J, et al. Mortality risk for dialysis patientswith different levels of serum calcium, phosphorus, andPTH: the Dialysis Outcomes and Practice PatternsStudy (DOPPS). Am J Kidney Dis. 2008;52(3):519-30.doi: 10.1053/j.ajkd.2008.03.020.

  15. Douthat WG, Castellano M, Berenguer L, GuzmánMA, Guzmán MA, de Arteaga J, et al. Elevadaprevalencia de hiperparatiroidismo secundario enpacientes con enfermedad renal crónica en diálisisen Argentina. Nefrología. 2013;33(5):657-66. doi:10.3265/Nefrologia.pre2013.May.12009.

  16. Kidney Disease: Improving Global Outcomes(KDIGO) CKD-MBD Update Work Group. KDIGO2017 Clinical Practice Guideline Update for theDiagnosis, Evaluation, Prevention, and Treatment ofChronic Kidney Disease–Mineral and Bone Disorder(CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001.

  17. Sociedad Argentina de Nefrología, Grupo deMetabolismo Óseo y Mineral. Segundo Consensode Metabolismo Óseo-Mineral, 2017. Buenos Aires:Ediciones Journal, 2018.

  18. Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y,Jacobson SH, et al. Recent changes in therapeuticapproaches and association with outcomes amongpatients with secondary hyperparathyroidism onchronic hemodialysis: the DOPPS study. Clin JAm Soc Nephrol. 2015;10(1):98-109. doi: 10.2215/CJN.12941213.




2020     |     www.medigraphic.com